期刊
JOURNAL OF NUCLEAR MEDICINE
卷 57, 期 5, 页码 708-714出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.115.163865
关键词
Ga-68-DOTATATE; In-111-pentetreotide; neuroendocrine; carcinoid; toxicity
资金
- U.S. Department of Veterans Affairs Merit Review [I01BX007080]
- Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network
- Vanderbilt Institute for Clinical and Translational Research grant support (NCATS/NIH) [UL1 TR000445]
Our purpose was to evaluate the safety and efficacy of Ga-68-DOTATATE PET/CT compared with In-111-pentetreotide imaging for diagnosis, staging, and restaging of pulmonary and gastroenteropancreatic neuroendocrine tumors. Methods: Ga-68-DOTATATE PET/CT and In-111-pentetreotide scans were obtained for 78 of 97 consecutively enrolled patients with known or suspected pulmonary or gastroenteropancreatic neuroendocrine tumors. Safety and toxicity were measured by comparing vital signs, serum chemistry values, or acquisition-related medical complications before and after Ga-68-DOTATATE injection. Added value was determined by changes in treatment plan when Ga-68-DOTATATE PET/CT results were added to all prior imaging, including 111In-pentetreotide. Interobserver reproducibility of Ga-68-DOTATATE PET/CT scan interpretation was measured between blinded and nonblinded interpreters. Results: Ga-68-DOTATATE PET/CT and In-111-pentetreotide scans were significantly different in impact on treatment (P < 0.001). Ga-68-DOTATATE PET/CT combined with CT or liver MRI changed care in 28 of 78 (36%) patients. Interobserver agreement between blinded and nonblinded interpreters was high. No participant had a trial-related event requiring treatment. Mild, transient events were tachycardia in 1, alanine transaminase elevation in 1, and hyperglycemia in 2 participants. No clinically significant arrhythmias occurred. Ga-68-DOTATATE PET/CT correctly identified 3 patients for peptide receptor radiotherapy incorrectly classified by In-111-pentetreotide. Conclusion: Ga-68-DOTATATE PET/CT was equivalent or superior to In-111-pentetreotide imaging in all 78 patients. No adverse events requiring treatment were observed. Ga-68-DOTATATE PET/CT changed treatment in 36% of participants. Given the lack of significant toxicity, lower radiation exposure, and improved accuracy compared with In-111-pentetreotide, Ga-68-DOTATATE imaging should be used instead of In-111-pentetreotide imaging where available.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据